Service d'Urologie Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalo-Universitaire Est, Faculté de médecine Pierre et Marie Curie, Université Paris VI, Paris, France.
Discovered over 40 years ago, hormonal therapy remains the cornerstone therapy of advanced prostate cancer and continues to evolve. Suppression of serum testosterone remains the mainstay of systemic treatment of prostate cancer. Antagonists of LH-RH are now available and can prevent the castration delay of agonists. They seem to have a clinical benefit in terms of PSA control. During the phase of resistance to extracellular castration, the androgen receptor is the dominant element. Intracellular steroidogenesis can be blocked by Abiraterone. Amplification and mutation of the androgen receptor may be controlled by antiandrogens of second generation. Thus, these new molecules, already or soon available, will renew the strategy of prostate cancer treatment.
Article in French.
Written by:
Audenet F, Rouprêt M, Tombal B. Are you the author?
Reference: Prog Urol. 2011 May;21 Suppl 3:S96-101.
doi: 10.1016/S1166-7087(11)70022-7
PubMed Abstract
PMID: 21616448
UroToday.com Prostate Cancer Section
